ARTICLE | Clinical News

ACH-1625: Phase I data

January 16, 2012 8:00 AM UTC

In an exploratory Phase I trial in 7 patients with HCV genotype 3 infection, twice-daily 400 mg ACH-1625 for 4.5 days achieved an antiviral response in 6 patients, with a 3.68 log10 IU/mL maximum reduction in mean HCV RNA levels. The compound was safe and well tolerated. ...